All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Vincent Camus, Centre Henri-Becquerel, Rouen, FR. We asked, What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma (PMBL)?
What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma?
PMBL is a rare form of B-cell lymphoma mostly affecting younger female patients, and the optimal treatment for it is uncertain. Camus presents a large retrospective analysis, across Lymphoma Study Association (LYSA) centers, on patients with newly diagnosed PMBL. This analysis compared CHOP delivered every 21 days (CHOP21), CHOP delivered every 14 days (CHOP14), and ACVBP, all combined with rituximab.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox